SABS (SAB Biotherapeutics) חוב לטווח קצר להון

SAB Biotherapeutics (SABS) is implementing a breakthrough antibody production method via transchromosomal cattle, ensuring sterility and supply volumes for oncology treatment. This daily price chart reflects a current value of 0.00. Highly qualified top executives are targeting therapies for infectious pathologies. However, SAB Biotherapeutics (SABS) faces a cash shortage, as the maintenance of research centers is leading to a gradual depletion of existing reserves.

For SAB Biotherapeutics (SABS), which lacks regular income due to its focus on antibody development, liquidity management is critical. This metric compares liabilities maturing within one year against equity, allowing investors to assess default risk or excessive management conservatism through the dynamics of short-term liabilities relative to equity to determine the company's financial stability.